Ownership and insider activity for Coeptis Therapeutics Holdings, Inc. (COEP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology.
Price
| Price | $10.99 |
| Market Cap | $39M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-04-24 | BSG Series CM, LLC | |||
| 2026-02-11 | Cogley Brian | A-Award | 12,500 | |
| 2026-02-11 | Cogley Brian | M-Exempt | 10,000 | $106K |
| 2026-02-11 | Deschamps Philippe | M-Exempt | 5,700 | $60K |
| 2026-02-11 | Deschamps Philippe | A-Award | 3,250 | |
| 2026-02-11 | Calise Chris | A-Award | 3,250 | |
| 2026-02-11 | Calise Chris | M-Exempt | 5,700 | $60K |
| 2026-02-11 | Mehalick David | M-Exempt | 148,875 | $1.0M |
| 2026-02-11 | Mehalick David | A-Award | 51,250 | |
| 2026-02-11 | Cochran Christopher P. | M-Exempt | 5,700 | $60K |
Balance Sheet (10y)
| Year | 2004 | 2005 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $383 | $153558 | 0 | $505 | $202965 | $2.2M | $3.8M | $1.5M | $532885 | $5.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $676596 |
| Receivables | 0 | 0 | 0 | 0 | $21786 | 0 | $8075 | $38978 | 0 | $7348 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $383 | $153558 | 0 | $505 | $224751 | $2.2M | $3.9M | $1.7M | $1.1M | $7.4M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | $73732 | $31851 | $71456 | $108877 | $59783 | $18399 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $46538 | 0 | 0 | 0 | 0 | $4.6M | $3.6M | $2.6M | $541875 | $361250 |
| Total Assets | $46921 | $153558 | $80000 | $171545 | $300484 | $6.8M | $7.9M | $8.1M | $8.9M | $19.8M |
| Accounts Payable | $215935 | $55215 | 0 | $450 | $1.6M | $134092 | $99021 | $1.4M | $1.3M | $888755 |
| Short-term Debt | $95000 | $650000 | $62073 | $152644 | $1.9M | $2.4M | $1.9M | $1.0M | $1.2M | $118875 |
| Total Current Liabilities | $310935 | $705215 | $62073 | $155852 | $5.3M | $2.8M | $2.2M | $3.0M | $4.5M | $1.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | $150000 | $1.6M | $150000 | $150000 | $150000 | $150000 |
| Total Liabilities | $310935 | $705215 | $62073 | $155852 | $5.4M | $4.4M | $3.5M | $3.8M | $5.0M | $2.1M |
| Retained Earnings | -$2.9M | -$3.3M | -$7073 | -$9307 | -$14.1M | -$27.6M | -$66.1M | -$87.4M | -$98.2M | -$110.0M |
| Total Equity | -$264014 | -$551657 | $17927 | $15692 | -$5.1M | $2.4M | $4.5M | $4.3M | $3.2M | $17.2M |
| Total Debt | $95000 | $650000 | $62073 | $152644 | $2.1M | $4.1M | $2.1M | $1.2M | $1.4M | $268875 |
| Net Debt | $94617 | $496442 | $62073 | $152139 | $1.9M | $1.9M | -$1.7M | -$244908 | $866168 | -$6.1M |
| Working Capital | -$310552 | -$551657 | -$62073 | -$155347 | -$5.1M | -$585384 | $1.8M | -$1.2M | -$3.5M | $5.6M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 4.16 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 7.84 |
Profitability
| Return on Equity | -69.09% |
| Return on Invested Capital | -71.70% |
| Return on Assets | -60.06% |
| Gross Margin | 86.75% |
| Operating Margin | -956.94% |
| Net Margin | -874.29% |
Related companies: CUE · EQ · IPSC · KPTI · MDCX · NRXP · OSTX
Explore sector: Technology · Software - Services
More sections of COEP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks